Effect of Mycophenolate Mofetil on Pulmonary Function in Scleroderma-Associated Interstitial Lung Disease
| Autor: | Jerry A. Molitor, Anthony J. Gerbino, Christopher H. Goss |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine medicine.medical_specialty Vital Capacity Critical Care and Intensive Care Medicine Gastroenterology Mycophenolic acid Pulmonary function testing DLCO Internal medicine Pulmonary fibrosis medicine Humans Lung Aged Retrospective Studies Scleroderma Systemic business.industry Respiratory disease Interstitial lung disease Middle Aged Mycophenolic Acid medicine.disease Confidence interval Surgery medicine.anatomical_structure Pulmonary Diffusing Capacity Female Lung Diseases Interstitial Cardiology and Cardiovascular Medicine business Immunosuppressive Agents medicine.drug |
| Zdroj: | Chest. 133:455-460 |
| ISSN: | 0012-3692 |
| Popis: | Objective We sought to determine the effectiveness of mycophenolate mofetil (MMF) in scleroderma- associated interstitial lung disease (SSc-ILD). Methods We retrospectively identified patients who met criteria for systemic sclerosis, had evidence of SSc-ILD on chest CT, received > 1 g/d of MMF for ≥ 6 months, and had pulmonary function data available. Vital capacity (VC) and diffusion capacity of the lung for carbon monoxide (D lco ) at treatment onset were compared with VC and D lco values 12 months before and 12 months after treatment onset. Twelve-month values were imputed from regression lines generated using all VC and D lco measurements made in the 24-month period either prior to or following treatment onset. Results Among 13 patients who met inclusion criteria, MMF was associated with a significant improvement in VC (mean, + 159 mL; confidence interval [CI], + 30 to + 289 mL; and + 4% of the predicted normal value; CI, + 2 to + 7%) after 12 months of treatment. In contrast, patients had a significant decrease in VC (mean, – 239 mL; CI, – 477 to – 0.5 mL; and − 5% of the predicted normal value; CI, – 11 to − 0.3%) in the 12 months prior to MMF treatment. D lco did not change significantly during MMF treatment (mean, + 1% of the predicted normal value; CI, – 2 to + 5%) but decreased significantly in the 12 months prior to treatment (mean, – 5% of the predicted normal value; CI, − 10 to − 1%). Conclusion These retrospective data suggest MMF improves VC in patients with SSc-ILD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|